These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 21314021)
1. Worth the wait. New, more effective therapies for hepatitis C are on the way. Learned J Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021 [No Abstract] [Full Text] [Related]
2. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Thomson JA; Perni RB Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus therapies. Smith RE Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802 [No Abstract] [Full Text] [Related]
4. Excitement grows for potential revolution in hepatitis C virus treatment. Opar A Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732 [No Abstract] [Full Text] [Related]
5. Treatment of hepatitis C 2010: a focus on protease inhibitors. Lemon M S D Med; 2010 Jun; 63(6):214-5. PubMed ID: 20853592 [No Abstract] [Full Text] [Related]
6. [New times for the treatment of chronic hepatitis C]. Gerstoft J; Fomsgaard A Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552 [No Abstract] [Full Text] [Related]
7. The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM; Chevaliez S; McHutchison JG Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890 [TBL] [Abstract][Full Text] [Related]
8. The way forward in HCV treatment--finding the right path. Manns MP; Foster GR; Rockstroh JK; Zeuzem S; Zoulim F; Houghton M Nat Rev Drug Discov; 2007 Dec; 6(12):991-1000. PubMed ID: 18049473 [TBL] [Abstract][Full Text] [Related]
10. A promising new anti-HCV protease inhibitor. Sulkowski M Hopkins HIV Rep; 2003 Jan; 15(1):7. PubMed ID: 12542005 [No Abstract] [Full Text] [Related]
11. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491 [No Abstract] [Full Text] [Related]
13. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Sarrazin C; Zeuzem S Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612 [TBL] [Abstract][Full Text] [Related]
14. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752 [TBL] [Abstract][Full Text] [Related]
15. Future directions in therapy for chronic hepatitis C. Jensen DM; Ascione A Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161 [TBL] [Abstract][Full Text] [Related]
16. Telaprevir: hope on the horizon, getting closer. Weisberg IS; Jacobson IM Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline. Huang M; Deshpande M Expert Rev Anti Infect Ther; 2004 Jun; 2(3):375-88. PubMed ID: 15482203 [TBL] [Abstract][Full Text] [Related]
19. New antiviral therapies for hepatitis C. O'Leary J; Chung RT Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):265-74. PubMed ID: 14695693 [No Abstract] [Full Text] [Related]
20. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Broering R; Zhang X; Kottilil S; Trippler M; Jiang M; Lu M; Gerken G; Schlaak JF Gut; 2010 Aug; 59(8):1111-9. PubMed ID: 20639253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]